课题基金 / 基金详情

Real-World Outcomes Associated with PARP Inhibitor Maintenance Therapy in Ovarian Cancer: A Population-Based Study

Real-World Outcomes Associated with PARP Inhibitor Maintenance Therapy in Ovarian Cancer: A Population-Based Study
卵巢癌 PARP 抑制剂维持治疗相关的真实结果：一项基于人群的研究
批准号：
472669
负责人：
Ethier Josee-Lyne
金额：
$7.29万
依托单位：
Queen's University (Kingston, Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
已结题
起止时间：
2022-09-01 至 2023-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=472669&lang=en
关键词：
Cost-Effectiveness Niraparib Olaparib Outcomes Ovarian Cancer Overall Survival Parp Inhibitors Progression-Free Survival Real-World Evidence Toxicity

项目摘要

项目成果

Ethier Josee-Lyne的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
High grade serous ovarian cancer (HGSOC) is a common and aggressive type of ovarian cancer which can be associated with BRCA mutations. Advanced HGSOC (stage III-IV) is typically treated with a combination of surgery and platinum-based chemotherapy. Howe
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Real world outcomes of novel targeted agents for the treatment of metastatic HER-2 positive breast cancer in Ontario: A population-based study
海外基金